HLA-B8 Antigen (HLA B8 Antigen)

Subscribe to Selected New Research on HLA-B8 Antigen

243 relevant articles (4 outcomes, 13 trials/studies) found for this Bio-Agent

Description: Human histocompatibility (HLA) surface antigen encoded by the B locus on chromosome 6. It is in linkage disequilibrium with HLA-A1 and HLA-DR3. This explains the fact that though HLA-B8 was originally associated with several diseases, including celiac disease, dermatitis herpetiformis, and myasthenia gravis, their association with HLA-DR3 is now considered more significant.

Also Known As:

HLA B8 Antigen; HLA-B8; Antigen, HLA-B8

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 931

Antigens: 95584

Surface Antigens: 3817

Histocompatibility Antigens: 1201

HLA Antigens: 2365

HLA-B Antigens: 676

HLA-B8 Antigen: 243

Histocompatibility Antigens Class I: 568

HLA-B Antigens: 676

HLA-B8 Antigen: 243

Isoantigens: 1073

Histocompatibility Antigens: 1201

HLA Antigens: 2365

HLA-B Antigens: 676

HLA-B8 Antigen: 243

Histocompatibility Antigens Class I: 568

HLA-B Antigens: 676

HLA-B8 Antigen: 243

Experts

1.	Peros-Golubicić, T: 1 article (10/2007)
2.	Martinez, N: 1 article (10/2007)
3.	Grubić, Z: 1 article (10/2007)
4.	Smojver-Jezek, S: 1 article (10/2007)
5.	Zunec, R: 1 article (10/2007)
6.	Kerhin-Brkljacić, V: 1 article (10/2007)
7.	Alilović, M: 1 article (10/2007)
8.	Tekavec-Trkanjec, J: 1 article (10/2007)
9.	Mueller, Claudia A: 1 article (01/2006)
10.	Berger, Thomas: 1 article (01/2006)

Related Diseases

1.	Graves Disease (Basedow Disease) 04/01/1983 - "This study demonstrates that Graves' disease can be subdivided using cluster analysis into clinically relevant subgroups which are further distinguished by their correlation with HLA-B8. " 09/01/1989 - "Our results demonstrate a strong association of the C4AQ0 allele with Graves' disease (56 versus 26%; P less than 0.002, relative risk = 3.7) and in particular in association with HLA-B8 and/or DR3 (92 versus 70.6%; P less than 0.04) when compared with normal controls. " 01/01/1983 - "Our data confirm the previously described association of HLA-B8 and DR3 with Graves' disease, particularly in patients with ophthalmopathy. " 01/01/1981 - "Reduced C4 in HLA-B8 positive patients with Graves' disease." 02/01/1980 - "The haplotypes, identified in eight-six patients and 113 relatives, indicate that the excess of HLA-B8 in patients and their relatives is primarily due to the halpotype 1-8. The relative risk for an HLA-B8 individual of developing Graves' disease is 2.02, whilst the relative risk for an individual of haplotype 1-8 is 4.23. " Order ALL the reference details at left...*
2.	Myasthenia Gravis 10/01/1998 - "Our results imply linkage disequilibrium of TNFbeta alleles with HLA-B8 and in myasthenia gravis we were unable to show a stronger association beyond HLA-B8." 08/01/1998 - "In a retrospective series of 86 patients with myasthenia gravis, the only factors predictive of improvement in muscular strength after transsternal thymectomy were preoperative severity of myasthenia (90% versus 54%, p = 0.0014) and HLA-B8 (79% versus 50%, p = 0.0060) in bivariable and multivariable analyses. " 04/01/1983 - "The observations also support those of others that HLA-B8 linked susceptibility gene is more frequently found in myasthenia gravis patients with thymic hyperplasia." 04/01/1983 - "HLA-B8 was increased nearly two fold in the myasthenia gravis patients (RR = 2.4) and was confined mainly to the young females without thymoma. " 06/01/1977 - "Recent studies have noted an increased association of the histocompatibility antigen HLA-B8 with myasthenia gravis in Caucasian patients. " Order ALL the reference details at left...
3.	Syndrome 01/01/1992 - "Our findings may help to clarify the role of EBV in the pathogenesis of primary Sjögren's syndrome which is closely associated with HLA-B8." 08/01/2002 - "This syndrome is closely related to HLA-B8, DR-3, and DR-17, but our case did not have these HLA loci. " 02/01/1998 - "The frequency of HLA-B8 and DR-3 in Japanese is almost 0%, explaining the rare onset of this syndrome in Japan. " 02/01/1998 - "This syndrome is common in Europe and is closely related to HLA-B8 and DR-3. " 11/01/1991 - "Two of the seven patients who fulfilled our criteria for Sjögren's syndrome were HLA-B8 positive. " Order ALL the reference details at left...
4.	Fibrosis (Cirrhosis) 06/01/1990 - "Remission (79% vs. 71%), relapse after drug withdrawal (76% vs. 71%), treatment failure (13% vs. 6%), progression to cirrhosis (46% vs. 32%), and death from liver failure (6% vs. 3%) occurred as frequently in patients with and without HLA-B8. " 05/01/1980 - "Men with alcoholic hepatitis with or without cirrhosis showed an increased incidence of the histocompatibility antigen HLA-B8 (P less than 0.02). " 06/19/1982 - "To test whether the increased prevalence of HLA-B8 reported in patients with alcoholic cirrhosis is due to the antigen being a genetic marker of susceptibility to liver damage from alcohol, patients who had cirrhosis of comparable clinical and histological severity were investigated for HLA-B8 status and cumulative alcohol intake. " 09/25/1976 - "Determination of histocompatibility antigens in 63 patients with alcoholic liver disease showed that HLA-B8 was more prevalent in patients with cirrhosis than in controls, but among those with fatty liver and minimal fibrosis the prevalence of this antigen was normal. " 06/01/1990 - "To assess the clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis, 81 consecutive patients were tested for histocompatibility antigens on the A and B loci, treated with corticosteroids, and followed prospectively for 111 +/- 8 mo. The 47 patients with HLA-B8 were younger (38 +/- 2 yr vs. 48 +/- 2 yr; p less than 0.01), had higher serum levels of aspartate aminotransferase (658 +/- 60 U/L vs. 465 +/- 49 U/L; p = 0.02) and bilirubin (7 +/- 1 mg/dl vs. 2.8 +/- 0.4 mg/dl; p = 0.003), and more commonly had histologic features of bridging necrosis, multilobular necrosis, and cirrhosis (85% vs. 56%; p less than 0.01) at presentation than the 34 patients without HLA-B8. " Order ALL the reference details at left...
5.	Liver Failure 06/01/1990 - "Remission (79% vs. 71%), relapse after drug withdrawal (76% vs. 71%), treatment failure (13% vs. 6%), progression to cirrhosis (46% vs. 32%), and death from liver failure (6% vs. 3%) occurred as frequently in patients with and without HLA-B8. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antithyroid Agents (Antithyroid Drugs)
2.	Histocompatibility Antigens (Histocompatibility Antigen)
3.	HLA Antigens (Human Leukocyte Antigens)
4.	HLA-B7 Antigen (HLA B7 Antigen)
5.	HLA-DR2 Antigen (HLA DR2 Antigen)
6.	HLA-B Antigens (HLA-B)
7.	HLA-Bw51
8.	Antigens
9.	HLA-DR3 Antigen (HLA DR3 Antigen)
10.	Antibodies

Related Therapies and Procedures

1.	Thymectomy
2.	Aftercare (After-Treatment)
3.	Transplants (Transplant)
4.	Liver Transplantation
5.	Breast Implantation (Implantation, Breast)

Best Treatments:
Research Summary Report
on Graves Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 217 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>